Appl. No. 09/998,966 Amdt. dated August 8, 2003 Reply to Office action of April 8, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1. (Currently Amended) An isolated nucleic acid comprising any one of the following:
 - (a) a nucleic acid sequence encoding the a polypeptide of SEQ ID NO: 2 or the complement of said nucleic acid sequence;
 - (b) a nucleic acid sequence at least 90% identical to the nucleic acid sequence of (a) above;
 - (c) a nucleic acid encoding a polypeptide wherein the polypeptide has conservative amino acid substitutions to the polypeptide of SEQ ID NO: 2; or
 - (d) a fragment of the nucleic acid sequence of (a), (b) or (c) above wherein the fragment comprises at least 20 nucleotides.
 - 2. (Original) The nucleic acid of claim 1, wherein said nucleic acid is selected from the group consisting of DNA and RNA.
 - 3. (Currently Amended) The nucleic acid of claim 1, wherein said An isolated nucleic acid comprising comprises an open reading frame that encodes a mature polypeptide of SEQ ID NO: 2 or its complement or a mutant or variant thereof.
 - 4. (Currently Amended) The nucleic acid of claim 1, wherein said An isolated nucleic acid comprising comprises a nucleic acid sequence which is SEQ ID NO: 1 or its complement.
 - (Currently Amended) The nucleic acid of claim 3 wherein said nucleic acid encodes
 amino acids 23-170 a mature form of the polypeptide comprising an amino acid of SEQ
 ID NO: 2.
 - 6. (Currently Amended) The nucleic acid of claim 4 wherein said An isolated nucleic acid encoding encodes a polypeptide, wherein said polypeptide has a single conservative amino acid substitution relative to the polypeptide of SEQ ID NO: 2, or its complement comprising an amino acid of SEQ ID NO: 2, a mutant or variant thereof.
 - 7. (Currently Amended) An <u>isolated nucleic acid</u> oligonucleotide sequence that is complementary to and hybridizes under stringent conditions with the nucleic acid of claim 1, wherein said stringent conditions comprise hybridization in a high salt buffer comprising 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C.



- 8. (Currently Amended) An isolated nucleic acid that hybridizes under stringent conditions with the nucleic acid The oligonucleotide sequence of claim 7 that is complementary to at least a portion of the nucleotide sequence of SEQ ID NO: 1, wherein said stringent conditions comprise hybridization in a high salt buffer comprising 6X SSC, 50 mM

 Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65°C.
- 9. (Canceled).
- 10. (Original) A vector comprising the nucleic acid of claim 1.
- 11. (Original) A cell comprising the vector of claim 10.
- 12. (Currently Amended) The cell of claim 11 wherein said cell is a prokaryotic or eukaryotic cell-comprising the nucleic acid sequence which is SEQ ID NO: 1, its complement, or a mutant or a variant thereof.
- (Currently amended) A pharmaceutical composition comprising the nucleic acid of claim
 1 and a pharmaceutically acceptable carrier.
- 14. (Amended herein). A process for producing a polypeptide encoded by the nucleic acid of claim 1, said process comprising:
 - a) providing the cell of claim 11;
 - b) culturing said cell under conditions sufficient to express said polypeptide; and
 - c) recovering said polypeptide,
 - thereby producing said polypeptide.
- 15. (Original) The process of claim 14 wherein said cell is a prokaryotic or eukaryotic cell.
- 16. (Canceled).
- 17. (Canceled).

